TLSI Overview

New Treatment Evaluation: TriSalus Life Sciences has published clinical data on its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization, showing it as a safe and effective option for patients with symptomatic thyroid disease, achieving 100% technical and clinical success in a study of 22 patients.

Future Research Initiatives: A multi-institutional registry study called PROTECT is underway to further validate these findings and explore the broader applicability of pressure-enabled embolization techniques in treating benign thyroid conditions.

TriSalus Life Sciences Exchange Offer: TriSalus Life Sciences has completed its exchange offer for Preferred Stock, allowing shareholders to convert their shares into common stock at a rate of 3.3 shares per preferred share, with approximately 98.82% of outstanding preferred shares tendered.

Amendment Approval and Future Plans: Due to sufficient shareholder agreement, the company will amend the terms of the Preferred Stock, resulting in remaining shares converting to common stock at a slightly lower rate, while continuing to focus on innovative drug delivery technologies for cancer treatment.

Exchange Offer Announcement: TriSalus Life Sciences has initiated an exchange offer for its Series A Convertible Preferred Stock, allowing shareholders to convert their preferred shares into common stock to simplify the company's capital structure and enhance transparency.

Consent Solicitation Details: The company is also seeking approval from preferred shareholders for an amendment that would enable automatic conversion of remaining preferred shares into common stock at a reduced exchange ratio, with a deadline for participation set for July 23, 2025.

New Product Launch: TriSalus Life Sciences has introduced the TriNav FLX Infusion System, enhancing trackability and flexibility for Interventional Radiologists in treating solid tumors while retaining the benefits of Pressure-Enabled Drug Delivery (PEDD).

Key Features and Impact: The system offers improved navigation through complex vascular structures with a 28% reduction in required navigation force, and it is reimbursable under specific HCPCS codes, supporting procedural planning and therapy delivery.